Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:28:59 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:MIRM from 2023-04-30 to 2024-04-29 - 52 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-10 21:30U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-02 08:30U:MIRMNews ReleaseMirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
2024-03-25 07:00U:MIRMNews ReleaseSagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
2024-03-13 18:00U:MIRMNews ReleaseMirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
2024-03-08 19:30U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-05 08:00U:MIRMNews ReleaseMirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2024-02-29 08:30U:MIRMNews ReleaseHepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI
2024-02-28 16:03U:MIRMNews ReleaseMirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
2024-02-21 16:05U:MIRMNews ReleaseMirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
2024-02-09 21:15U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-19 21:30U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-16 08:30U:MIRMNews ReleaseMirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
2024-01-10 19:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-08 08:30U:MIRMNews ReleaseMirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
2024-01-03 08:45U:MIRMNews ReleaseMirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-18 08:30U:MIRMNews ReleaseMirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia
2023-12-08 19:30U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-30 09:46U:MIRMNews ReleaseStonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
2023-11-20 16:05U:MIRMNews ReleaseMirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference
2023-11-13 14:00U:MIRMNews ReleaseMirum Pharmaceuticals Presents New Data at The Liver Meeting ‚ ®
2023-11-10 17:30U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-03 08:30U:MIRMNews ReleaseMirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference
2023-10-30 08:30U:MIRMNews ReleaseMirum Pharmaceuticals to Present New Data at The Liver Meeting ‚ ®
2023-10-27 08:45U:MIRMNews ReleaseMirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
2023-10-17 16:30U:MIRMNews ReleaseMirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
2023-10-10 20:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-07 17:00U:MIRMNews ReleaseMirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN
2023-10-02 08:30U:MIRMNews ReleaseMirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis
2023-09-26 08:30U:MIRMNews ReleaseMirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
2023-09-21 08:30U:MIRMNews ReleaseMirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
2023-09-11 10:07U:MIRMNews ReleaseMirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer
2023-09-08 23:30U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-06 08:30U:MIRMNews ReleaseMirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-09-05 08:30U:MIRMNews ReleaseMirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
2023-09-05 08:30U:MIRMNews ReleaseTravere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
2023-08-10 19:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-03 16:05U:MIRMNews ReleaseMirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-07-27 16:05U:MIRMNews ReleaseMirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023
2023-07-25 08:30U:MIRMNews ReleaseMirum ¢ € ™s LIVMARLI ‚ ® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome
2023-07-17 08:00U:MIRMNews ReleaseMirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
2023-07-17 08:00U:MIRMNews ReleaseTravere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals
2023-07-10 20:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-23 12:00U:MIRMNews ReleaseMirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress
2023-06-14 08:30U:MIRMNews ReleaseEvent-Free Survival Data from Mirum ¢ € ™s LIVMARLI Alagille Syndrome Program Published in Hepatology
2023-06-09 21:30U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-07 08:30U:MIRMNews ReleaseMirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress
2023-05-19 07:00U:MIRMNews ReleaseData from Mirum ¢ € ™s LIVMARLI Studies Presented at ESPGHAN Annual Meeting
2023-05-18 08:30U:MIRMNews ReleaseHepatology Communications Publishes Data from Mirum ¢ € ™s LIVMARLI in Primary Sclerosing Cholangitis
2023-05-17 08:30U:MIRMNews ReleaseMirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting
2023-05-11 08:30U:MIRMNews ReleaseMirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study
2023-05-10 21:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-04 16:02U:MIRMNews ReleaseMirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update